TY - JOUR
T1 - Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention
AU - Saw, Jacqueline
AU - Topol, Eric J.
AU - Steinhubl, Steven R.
AU - Brennan, Danielle
AU - Berger, Peter B.
AU - Moliterno, David J.
N1 - Funding Information:
The CREDO trial was supported by Sanofi-Synthelabo, Inc./Bristol Myers Squibb Partnership, New York, New York.
PY - 2004/9/1
Y1 - 2004/9/1
N2 - Patients in the Clopidogrel for the Reduction of Events During Observation trial were subgrouped according to whether they underwent index percutaneous coronary artery revascularization procedures only or this procedure plus subsequent percutaneous or surgical revascularization procedures during 1-year follow-up. The relative risk reduction in ischemic events associated with up-front and long-term clopidogrel compared with placebo was 2-fold greater in patients who required repeat revascularization procedures compared with those who did not (42.4% vs 21.7%).
AB - Patients in the Clopidogrel for the Reduction of Events During Observation trial were subgrouped according to whether they underwent index percutaneous coronary artery revascularization procedures only or this procedure plus subsequent percutaneous or surgical revascularization procedures during 1-year follow-up. The relative risk reduction in ischemic events associated with up-front and long-term clopidogrel compared with placebo was 2-fold greater in patients who required repeat revascularization procedures compared with those who did not (42.4% vs 21.7%).
UR - http://www.scopus.com/inward/record.url?scp=4444338086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4444338086&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2004.05.026
DO - 10.1016/j.amjcard.2004.05.026
M3 - Article
C2 - 15342293
AN - SCOPUS:4444338086
SN - 0002-9149
VL - 94
SP - 623
EP - 625
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 5
ER -